According to announcements from Concept Medical and independent reporting from corporate news services, new clinical trial results evaluating femoropopliteal peripheral artery disease (PAD) will take center stage at the VIVA 2026 conference running October 3–6 at Bellagio Las Vegas. Researchers will present a targeted subgroup analysis from the SirPAD randomized trial, focusing specifically on 597 patients treated for femoropopliteal disease who experience intermittent claudication without tissue loss.
SirPAD Subgroup Analysis Targets Femoropopliteal PAD
The upcoming presentation at VIVA 2026 builds upon the broader SirPAD randomized trial, which enrolled 1,252 patients with symptomatic infrainguinal PAD, according to trial documentation. That primary trial evaluated angioplasty using the MagicTouch sirolimus-coated balloon against an uncoated balloon. Prof. Dr. Stefano Barco, Co-PI of the trial, will present the new femoropopliteal-specific data during the late-breaking clinical trial program at the Las Vegas meeting.
While the broader trial evaluated a wide spectrum of infrainguinal disease, the 597-patient subgroup isolates individuals whose primary presentation is intermittent claudication. For this specific population, clinical priorities extend past basic limb preservation toward achieving durable symptom relief, as detailed in trial briefings.
Did you know? The overarching SirPAD trial results were recently published in the New England Journal of Medicine, demonstrating that treatment with the MagicTouch sirolimus-coated balloon achieved a significant reduction in major adverse limb events at the one-year mark compared to standard uncoated balloons.
Evaluating Sirolimus-Coated Balloons Against Uncoated Devices
The investigator-initiated SirPAD trial was designed to directly compare the MagicTouch PTA sirolimus-coated balloon against standard uncoated balloon angioplasty. According to trial data released by Concept Medical, the study established both non-inferiority and superiority for the sirolimus-coated device regarding major adverse limb events (MALE) across its primary patient cohort.
Endovascular specialists attending VIVA 2026—an international conference dedicated to peripheral vascular disease and endovascular therapy—will scrutinize the femoropopliteal subgroup data.
Frequently Asked Questions
What is the primary focus of the SirPAD subgroup presentation at VIVA 2026?
According to the study disclosures, the presentation focuses on a subgroup of 597 patients from the main trial who were treated for femoropopliteal peripheral artery disease presenting with intermittent claudication without tissue loss.
Who is presenting the new trial data?
Prof. Dr. Stefano Barco, serving as Co-PI, will present the findings during the late-breaking clinical trial sessions at VIVA 2026.
What devices were compared in the SirPAD trial?
The academic trial compared the MagicTouch PTA sirolimus-coated balloon, developed by Concept Medical Group, against standard uncoated balloons in patients with femoropopliteal or below-the-knee disease.
Stay Updated on Vascular Research
Explore more clinical trial breakdowns and endovascular updates by subscribing to our specialized newsletter or leaving a comment below.
Worth a look